Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Adcetris Now FDA Approved for Pediatric Patients with Classical Hodgkin Lymphoma

December 2022 Vol 8 No 6

In November 2022, the FDA approved Adcetris (brentuximab vedotin; from Seagen), a CD30-directed antibody–drug conjugate, in combination with a chemotherapy regimen for pediatric patients aged 2 years or older with high-risk classical Hodgkin lymphoma who have not received previous therapy. This is the first approval of Adcetris for pediatric patients. It was previously approved for this condition in adults.

The FDA approved Adcetris plus chemotherapy for young patients based on results of a randomized, open-label, actively controlled clinical trial that included 600 patients with classical Hodgkin lymphoma. The patients were divided into 2 groups to receive either Adcetris plus chemotherapy or chemotherapy alone.

The average time of event-free survival, defined as the time from randomization to the earliest of disease progression or disease relapse (coming back), second cancer, or death from any cause, was not reached in either group, meaning that most patients continued to benefit from their treatment and did not have disease progression or other serious events.

The most common serious side effects with Adcetris plus chemotherapy in pediatric patients were neutropenia, anemia, thrombocytopenia, febrile neutropenia, stomatitis, and infection.

Recommended For You